Wolfe Research analyst Kalpit Patel initiated coverage of Summit Therapeutics (SMMT) with a Peer Perform rating and no price target The firm’s analysis suggests the Harmoni-2 may not show an overall survival benefit, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Positive Outlook for Summit Therapeutics Amid Strategic Clinical Advancements
- Summit Therapeutics Reports Positive Phase III Trial Results
- Akeso to announces results from OS analysis of Phase III HARMONi-A study
- Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See
- Summit Therapeutics files to sell 26.68M shares of common stock for holders